Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +13.3%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.1%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (537)

clinicaltrialsPublishedShowing 1,451–1,455 of 1,455 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00096837	A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma	completed	Phase 2	25	Pharmacyclics LLC.INDUSTRY	1	Jun 8, 2006	clinicaltrials
NCT00323505	A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma	completed	Phase 2	—	Royal Marsden NHS Foundation TrustOTHER	1	May 9, 2006	clinicaltrials